INFERTILITY DRUGS MARKET ANALYSIS

Infertility Drugs Market, By Drug Type (Clomiphene citrate, Sex hormones, Gonadotropins, Bromocriptine, Cabergoline, Imipramine, Letrozole, Metformin), By Route of Administration (Oral and Parenteral), By Gender (Male and Female), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In : Jul 2024
Code : CMI2665
Pages :145
Formats :
Excel and PDF
Industry : Pharmaceutical

Regional Analysis

Infertility Drugs Market Regional Insights

To learn more about this report, request sample copy

North America dominates the global infertility drugs market with an estimated market share of 39.2% in 2024. The U.S. accounts for the major share due to the strong foothold of leading pharmaceutical companies in the country. In vitro fertilization (IVF) and other assisted reproductive technologies are highly popular in the U.S. for conceiving babies. This has boosted sales of fertility medications over the years. The availability of advanced fertility treatment options and rising public awareness about infertility issues can drive the market growth in North America. Favorable reimbursement policies for infertility drugs and procedures can drive the market growth.

Asia Pacific is poised to be the fastest growing regional market. China and India are widely seen as most lucrative emerging markets. Rapid economic development, increasing health expenditures, growing medical tourism, and rising infertility rates due to lifestyle changes and late pregnancies boosts demand for infertility drugs in Asia Pacific. There is abundant opportunity waiting to be tapped given the huge patient population suffering from infertility-related issues. Local players are strengthening their presence while global manufacturers are expanding operations in Asia to leverage the high growth potential.